MTF Biologics is set to introduce a new acellular human reticular dermal allograft called AlloPatch Pliable Meshed.
The new allograft will be launched at the Symposium on Advanced Wound Care Spring | Wound Healing Society in National Harbor, Maryland, US. The event will be held next week.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AlloPatch is designed for the treatment of wounds such as diabetic foot ulcers and venous leg ulcers.
MTF Biologics research and development executive vice-president Marc Long said: “We are delighted to add to our wound care portfolio to continue to collaborate with healthcare providers to expand treatment solutions for patients.
“We understand the difficulties of treating high-risk patients with chronic, non-healing wounds and our comprehensive portfolio of dermal, placental and adipose tissues empower clinicians to treat a variety of patients.”
AlloPatch Pliable Meshed has a unique meshed design that enables optimal wound drainage. It is claimed to be the only aseptically processed meshed reticular dermal tissue that is suitable for use in both acute and post-acute settings.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDesigned to conform to wound topography for immediate coverage, the allograft can expand up to 170% of its original size based on wound size and topography.
The allograft offers a scaffold for wound closure, which supports the patient’s own cells to proliferate and repopulate the graft to enable integration into the host tissue.
Furthermore, the allograft provides structural coverage that enables early re-epithelialisation of the wound without the requirement for substantial granulation tissue formation by the host.
